• May 15, 2023

    The second scientific conference “Fundamentals of Cardiovascular Pharmacotherapy – Combination Therapy” was held in Sofia between May 12-14, 2023 on the initiative of the Academy-Cardiology Foundation, Logartis Foundation and Arbilis Ltd, in collaboration with the Bulgarian Society of Pharmacy and the National Association of General Practitioners in Bulgaria.

    As a leading manufacturer of combination products (polypills) in the cardiovascular field, Tchaikapharma High Quality Medicines naturally took part in the event as a gold partner. Among the topics of this year’s conference were “Combination Therapy of Arterial Hypertension”, “Combination Therapy of Coronary Heart Disease”, “Combination Antithrombosis Therapy”, etc.

    Pharmacotherapy is the basis of daily clinical practice of all physicians. Good knowledge of the mechanisms of action of drugs, indications for their administration, drug interactions and their dosing according to specific comorbidities is very important for daily practice.

  • January 10, 2023

    “We have assured quantities of medicines manufactured at Tchaikapharma High Quality Medicines. Based on current consumption, we maintain a minimum of a 4-month supply. If there is increased demand, we are ready to respond.”

  • December 6, 2022

    Tchaikapharma’s latest medicinal product to receive marketing authorisation from the Bulgarian Drug Agency is Clopasa (colchicine) 0.5 mg tablets – the first gout treatment in the company’s broad portfolio.


    Clopasa belongs to the group of medicines with antipathic action. It is used for the treatment of acute attacks of gout, in the condition of chronic gout, for the prevention of acute attacks when starting treatment with other drugs lowering uric acid in the blood and urine or when treating periodic diseases (Familial Mediterranean Fever).


    The medicinal product is available on prescription.
    ATC code: M04AC01

  • October 21, 2022

    The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is:

    Semefro 50 mg/850 mg film-coated tablets

    Semefro 50 mg/1000 mg film-coated tablets


    Active ingredients: sitagliptin/metformin hydrochloride


    Semefro contains two different medicines called sitagliptin and metformin.

    – Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors)

    – metformin belongs to a class of medicines called biguanidines.


    They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes”. This medication increases the levels of insulin produced after a meal and reduces the amount of sugar produced by the body.


    Along with diet and exercise, the drug helps lower blood sugar.

    The medication can be used alone or with certain other diabetes medications, (insulin, sulfonylurea, or glitazone).


    This is a prescription-only medicinal product.


    ATC code: A10BD07

  • October 19, 2022

    The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease.


    Read the full article here in Bulgarian.